BPC-157 vs TB-500
The two healing peptides everyone asks about — what they actually do, how they differ, and why most protocols run them together.
TL;DR
BPC-157 is the angiogenesis + growth-factor-receptor-upregulation peptide — it drives new blood vessel formation and fibroblast activity at the injury site. TB-500 is the cell-migration peptide — it mobilizes stem cells and progenitor cells systemically and helps them reach the wound. They're functionally complementary, which is why the canonical injury protocol runs both at once.
Side-by-side
How they work — side-by-side
BPC-157 ('Body Protection Compound-157') is a 15-amino-acid synthetic peptide derived from a stable gastric protein. Its dominant effect is angiogenesis — driving the formation of new blood vessels at injury sites — paired with VEGF and nitric oxide pathway modulation and upregulation of growth-hormone receptor expression on fibroblasts. Practical interpretation: BPC-157 increases blood supply and growth-factor sensitivity exactly where the body is trying to repair tissue.
TB-500 is a synthetic version of a 43-residue fragment of Thymosin Beta-4, a naturally occurring protein with the highest concentration in platelets and white blood cells. Its dominant effect is cell migration — it binds G-actin, modulates the cytoskeleton, and increases the mobilization of stem and progenitor cells from bone marrow toward sites of injury or inflammation. Practical interpretation: TB-500 helps the cells that do the repairing actually get to where the repair is needed.
These mechanisms are not redundant — they're complementary. BPC-157 builds the vascular highway and primes the local environment. TB-500 sends the construction crew down that highway. That's why the canonical orthopedic injury protocol stacks both: 250–500 mcg BPC-157 twice daily plus 2–2.5 mg TB-500 twice weekly for 4–6 weeks during acute recovery, then taper.
When to choose which
BPC-157
Choose BPC-157 if
BPC-157 is the better single-agent choice when the injury is local, the tissue is gut/tendon/ligament/joint, and consistent daily dosing is feasible.
- Tendon, ligament, or joint injury (Achilles, rotator cuff, elbow tendon)
- Gut healing — IBD, leaky gut, post-NSAID damage, gastritis
- You can commit to daily (often twice-daily) subcutaneous injections
- You want stronger published clinical literature behind your choice
- You want the option to inject near the injury site for local effect
TB-500
Choose TB-500 if
TB-500 is the better single-agent choice when the injury is systemic, the goal is whole-body recovery, or the dosing schedule needs to be less frequent.
- Muscle tear, strain, or systemic soft-tissue damage
- Recovery from over-training or chronic inflammation
- Twice-weekly injection schedule is preferred over daily
- Goal is cell-migration / stem-cell mobilization specifically
- You're already running BPC-157 and want a complementary mechanism
Synergistic — stack both
BPC-157 and TB-500 are the canonical healing-peptide stack. The mechanisms target different stages of the repair cascade — BPC-157 handles vascularization and local growth-factor sensitization, TB-500 handles progenitor-cell delivery. Standard injury-recovery protocol: 250–500 mcg BPC-157 twice daily + 2–2.5 mg TB-500 twice weekly, both subcutaneous, for 4–6 weeks. Inject at different sites; rotate locations to prevent injection-site irritation.
Safety + side-effect contrast
Both peptides have favorable real-world safety profiles in practitioner reports. The mechanism difference doesn't translate into very different side-effect profiles — most issues are injection-related rather than systemic.
- BPC-157 occasionally causes head-pressure or flushing in the first week — usually resolves with dose split.
- TB-500 occasionally produces fatigue or 'flu-like' fog in the first dose or two, attributed to systemic immune activation.
- Both can produce injection-site redness, itching, or transient bruising. Rotate injection sites.
- Neither has published long-term human safety data. Cycle on/off rather than running indefinitely.
- Neither is appropriate during active malignancy — both modulate growth-factor and angiogenesis pathways.
Frequently asked
Should I take BPC-157 or TB-500?
If you're picking only one: BPC-157 for tendon/ligament/gut injuries with daily injections feasible; TB-500 for muscle/systemic damage with twice-weekly dosing. If you can do both, the canonical injury protocol runs them together — they target different stages of the repair cascade.
Can you stack BPC-157 and TB-500?
Yes, this is the canonical healing stack. Standard protocol: 250–500 mcg BPC-157 twice daily plus 2–2.5 mg TB-500 twice weekly, both subcutaneous, for 4–6 weeks. Inject at different sites and rotate locations.
Which works faster?
BPC-157 typically produces noticeable improvement within days because it works locally at the injury site. TB-500 takes 1–2 weeks because its mechanism — cell migration and stem-cell mobilization — operates on a longer timeline. The stack tends to outperform either alone.
Is TB-500 the same as Thymosin Beta-4?
TB-500 is a synthetic version of a 43-amino-acid fragment of natural Thymosin Beta-4. The full TB-4 protein is 44 residues; TB-500 is the 'active fragment' that researchers and practitioners use because it's smaller, easier to manufacture, and has demonstrated the same cell-migration effects in studies.
How long can I run BPC-157 and TB-500?
Standard cycle is 4–6 weeks, with some protocols extending to 8 weeks for severe injuries. Cycle off for at least 2–4 weeks between cycles. There's no published long-term human safety data, so indefinite running is not recommended.
Cited research
Sikiric et al. — Brain–gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol 2016.
Chang et al. — Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 2014.
Goldstein et al. — Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005.
Crockford et al. — Thymosin beta-4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 2010.
Need a personalized bpc-157 vs tb-500 call?
The Coach takes your bloodwork, goals, and tolerance into account and outputs a cited protocol card — saved as a branded PDF you can take to your doctor.
Ask the Coach